<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">32809473</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK560638</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-26629">Paraneoplastic Cerebellar Degeneration</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Aly</LastName><ForeName>Ragia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Danbury Hospital</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmady</LastName><ForeName>Prabhu D.</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>UNC school of Medicine, Atrium Health</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Paraneoplastic syndromes constitute a group of uncommon manifestations that are noted in patients with different types of malignancies. The underlying mechanism is not a direct spread but could be hormonal, caused by active proteins or peptides secreted by malignant cells such as antidiuretic hormone (ADH), parathyroid hormone-related peptide (PTHrP) or adrenocorticotrophic hormone (ACTH). They also can be autoimmune, caused by crossreacting antibodies or immune cells produced in the human body in response to malignant tumors, such as Lambert Eaton syndrome, paraneoplastic cerebellar degeneration, and limbic encephalitis. They can also be related to cytokines produced by tumor cells or the immune system. Paraneoplastic syndromes can occur with multiple types of malignancies, including but not limited to breast cancer, small cell lung cancer, squamous cell lung cancer, Hodgkin lymphoma, mesothelioma, renal cell carcinoma, and multiple other malignancies.  Clinicians need to be familiar with the presentations of paraneoplastic syndromes as they can be the first presenting symptoms of an underlying malignancy. Failure to identify these syndromes may result in delayed diagnosis of cancer and poor clinical outcomes. These syndromes are not directly related to tumor invasion, metastatic disease symptoms, or due to adverse treatment effects. Paraneoplastic neurological syndromes (PNS) are a unique subset of paraneoplastic syndromes. Caused by cross-reactive antibodies called onconeural antibodies, these are antibodies produced by the immune system in response to malignant tumors. These onconeural antibodies can attack different parts of the nervous system resulting in various neurological manifestations. Paraneoplastic cerebellar degeneration (PCD) is one of the more commonly seen paraneoplastic neurological syndromes. It is caused by immune-mediated injury to cerebellar Purkinje cells. It is associated with multiple malignancies but, most commonly, breast and pelvic malignancies. PCD has also been reported in patients with Hodgkin lymphoma, gastric cancer, prostate cancer, and small cell lung cancer. PCD can progress rapidly over a few weeks and can result in severe disability.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s10">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s11">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s12">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s13">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s14">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s15">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>8</Day></ContributionDate><ReferenceList><Reference><Citation>Zekeridou A, Majed M, Heliopoulos I, Lennon VA. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. Thorac Cancer. 2019 Apr;10(4):1001-1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449272</ArticleId><ArticleId IdType="pubmed">30810271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85(9):838-54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931619</ArticleId><ArticleId IdType="pubmed">20810794</ArticleId></ArticleIdList></Reference><Reference><Citation>Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ, European Federation of Neurological Societies  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011 Jan;18(1):19-e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086523</ArticleId><ArticleId IdType="pubmed">20880069</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012 Dec;25(6):795-801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705179</ArticleId><ArticleId IdType="pubmed">23041955</ArticleId></ArticleIdList></Reference><Reference><Citation>Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, PNS Euronetwork  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010 Mar;67(3):330-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanous I, Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2015;5:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078897</ArticleId><ArticleId IdType="pubmed">27800287</ArticleId></ArticleIdList></Reference><Reference><Citation>Arratibel N, Sobejano E, Moran JC, Diaz LG, Blázquez A, Baile M, Veiga Á, Caballero MD, García-Sanz R. A Case of Paraneoplastic Cerebellar Degeneration that Preceded the Diagnosis of Classical Hodgkin's Lymphoma by 16 Months. Am J Case Rep. 2020 Jun 23;21:e922342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328688</ArticleId><ArticleId IdType="pubmed">32574156</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak M, Kowar M, Sippel C, Wilhelm K, Ko YD, Jacobs AH. [Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies]. Nervenarzt. 2020 Feb;91(2):156-160.</Citation><ArticleIdList><ArticleId IdType="pubmed">31900515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol. 2012 Jan;15(1):6-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299076</ArticleId><ArticleId IdType="pubmed">22412264</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct;42(10):1931-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407575</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol. 2016 Aug;3(8):655-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999597</ArticleId><ArticleId IdType="pubmed">27606347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015 Sep 17;12:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573944</ArticleId><ArticleId IdType="pubmed">26377319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology. 1988 Sep;38(9):1380-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3045692</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal S, Recio M, Shamim S. Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. Proc (Bayl Univ Med Cent) 2015 Apr;28(2):217-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365125</ArticleId><ArticleId IdType="pubmed">25829659</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien TJ, Pasaliaris B, D'Apice A, Byrne E. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J Clin Neurosci. 1995 Oct;2(4):316-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18638835</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91(5):519-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med. 2007 Feb 08;356(6):612-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287482</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulaziz ATA, Yu XQ, Zhang L, Jiang XY, Zhou D, Li JM. Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: Case report. Medicine (Baltimore) 2018 Jun;97(24):e10717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024112</ArticleId><ArticleId IdType="pubmed">29901574</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):525-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077501</ArticleId><ArticleId IdType="pubmed">16543536</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739186</ArticleId><ArticleId IdType="pubmed">15258215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409-18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764061</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003 Jun;63(2):187-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825823</ArticleId></ArticleIdList></Reference><Reference><Citation>Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, Delattre JY. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):479-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736897</ArticleId><ArticleId IdType="pubmed">10727484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato N, Hashida G, Konaka K. Rehabilitation for a patient with anti-Yo antibody-positive paraneoplastic cerebellar degeneration caused by breast cancer: A case report and literature review. Medicine (Baltimore) 2017 Nov;96(44):e8468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682818</ArticleId><ArticleId IdType="pubmed">29095299</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32809473</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">32809473</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK560638</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-26629">Paraneoplastic Cerebellar Degeneration</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Aly</LastName><ForeName>Ragia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Danbury Hospital</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmady</LastName><ForeName>Prabhu D.</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>UNC school of Medicine, Atrium Health</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Paraneoplastic syndromes constitute a group of uncommon manifestations that are noted in patients with different types of malignancies. The underlying mechanism is not a direct spread but could be hormonal, caused by active proteins or peptides secreted by malignant cells such as antidiuretic hormone (ADH), parathyroid hormone-related peptide (PTHrP) or adrenocorticotrophic hormone (ACTH). They also can be autoimmune, caused by crossreacting antibodies or immune cells produced in the human body in response to malignant tumors, such as Lambert Eaton syndrome, paraneoplastic cerebellar degeneration, and limbic encephalitis. They can also be related to cytokines produced by tumor cells or the immune system. Paraneoplastic syndromes can occur with multiple types of malignancies, including but not limited to breast cancer, small cell lung cancer, squamous cell lung cancer, Hodgkin lymphoma, mesothelioma, renal cell carcinoma, and multiple other malignancies.  Clinicians need to be familiar with the presentations of paraneoplastic syndromes as they can be the first presenting symptoms of an underlying malignancy. Failure to identify these syndromes may result in delayed diagnosis of cancer and poor clinical outcomes. These syndromes are not directly related to tumor invasion, metastatic disease symptoms, or due to adverse treatment effects. Paraneoplastic neurological syndromes (PNS) are a unique subset of paraneoplastic syndromes. Caused by cross-reactive antibodies called onconeural antibodies, these are antibodies produced by the immune system in response to malignant tumors. These onconeural antibodies can attack different parts of the nervous system resulting in various neurological manifestations. Paraneoplastic cerebellar degeneration (PCD) is one of the more commonly seen paraneoplastic neurological syndromes. It is caused by immune-mediated injury to cerebellar Purkinje cells. It is associated with multiple malignancies but, most commonly, breast and pelvic malignancies. PCD has also been reported in patients with Hodgkin lymphoma, gastric cancer, prostate cancer, and small cell lung cancer. PCD can progress rapidly over a few weeks and can result in severe disability.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s10">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s11">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s12">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s13">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s14">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s15">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>8</Day></ContributionDate><ReferenceList><Reference><Citation>Zekeridou A, Majed M, Heliopoulos I, Lennon VA. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. Thorac Cancer. 2019 Apr;10(4):1001-1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449272</ArticleId><ArticleId IdType="pubmed">30810271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85(9):838-54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931619</ArticleId><ArticleId IdType="pubmed">20810794</ArticleId></ArticleIdList></Reference><Reference><Citation>Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ, European Federation of Neurological Societies  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011 Jan;18(1):19-e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086523</ArticleId><ArticleId IdType="pubmed">20880069</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012 Dec;25(6):795-801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705179</ArticleId><ArticleId IdType="pubmed">23041955</ArticleId></ArticleIdList></Reference><Reference><Citation>Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, PNS Euronetwork  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010 Mar;67(3):330-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanous I, Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2015;5:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078897</ArticleId><ArticleId IdType="pubmed">27800287</ArticleId></ArticleIdList></Reference><Reference><Citation>Arratibel N, Sobejano E, Moran JC, Diaz LG, Blázquez A, Baile M, Veiga Á, Caballero MD, García-Sanz R. A Case of Paraneoplastic Cerebellar Degeneration that Preceded the Diagnosis of Classical Hodgkin's Lymphoma by 16 Months. Am J Case Rep. 2020 Jun 23;21:e922342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328688</ArticleId><ArticleId IdType="pubmed">32574156</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak M, Kowar M, Sippel C, Wilhelm K, Ko YD, Jacobs AH. [Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies]. Nervenarzt. 2020 Feb;91(2):156-160.</Citation><ArticleIdList><ArticleId IdType="pubmed">31900515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol. 2012 Jan;15(1):6-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299076</ArticleId><ArticleId IdType="pubmed">22412264</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct;42(10):1931-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407575</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol. 2016 Aug;3(8):655-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999597</ArticleId><ArticleId IdType="pubmed">27606347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015 Sep 17;12:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573944</ArticleId><ArticleId IdType="pubmed">26377319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology. 1988 Sep;38(9):1380-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3045692</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal S, Recio M, Shamim S. Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. Proc (Bayl Univ Med Cent) 2015 Apr;28(2):217-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365125</ArticleId><ArticleId IdType="pubmed">25829659</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien TJ, Pasaliaris B, D'Apice A, Byrne E. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J Clin Neurosci. 1995 Oct;2(4):316-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18638835</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91(5):519-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med. 2007 Feb 08;356(6):612-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287482</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulaziz ATA, Yu XQ, Zhang L, Jiang XY, Zhou D, Li JM. Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: Case report. Medicine (Baltimore) 2018 Jun;97(24):e10717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024112</ArticleId><ArticleId IdType="pubmed">29901574</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):525-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077501</ArticleId><ArticleId IdType="pubmed">16543536</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739186</ArticleId><ArticleId IdType="pubmed">15258215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409-18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764061</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003 Jun;63(2):187-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825823</ArticleId></ArticleIdList></Reference><Reference><Citation>Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, Delattre JY. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):479-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736897</ArticleId><ArticleId IdType="pubmed">10727484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato N, Hashida G, Konaka K. Rehabilitation for a patient with anti-Yo antibody-positive paraneoplastic cerebellar degeneration caused by breast cancer: A case report and literature review. Medicine (Baltimore) 2017 Nov;96(44):e8468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682818</ArticleId><ArticleId IdType="pubmed">29095299</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32809473</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">32809473</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK560638</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-26629">Paraneoplastic Cerebellar Degeneration</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Aly</LastName><ForeName>Ragia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Danbury Hospital</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmady</LastName><ForeName>Prabhu D.</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>UNC school of Medicine, Atrium Health</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Paraneoplastic syndromes constitute a group of uncommon manifestations that are noted in patients with different types of malignancies. The underlying mechanism is not a direct spread but could be hormonal, caused by active proteins or peptides secreted by malignant cells such as antidiuretic hormone (ADH), parathyroid hormone-related peptide (PTHrP) or adrenocorticotrophic hormone (ACTH). They also can be autoimmune, caused by crossreacting antibodies or immune cells produced in the human body in response to malignant tumors, such as Lambert Eaton syndrome, paraneoplastic cerebellar degeneration, and limbic encephalitis. They can also be related to cytokines produced by tumor cells or the immune system. Paraneoplastic syndromes can occur with multiple types of malignancies, including but not limited to breast cancer, small cell lung cancer, squamous cell lung cancer, Hodgkin lymphoma, mesothelioma, renal cell carcinoma, and multiple other malignancies.  Clinicians need to be familiar with the presentations of paraneoplastic syndromes as they can be the first presenting symptoms of an underlying malignancy. Failure to identify these syndromes may result in delayed diagnosis of cancer and poor clinical outcomes. These syndromes are not directly related to tumor invasion, metastatic disease symptoms, or due to adverse treatment effects. Paraneoplastic neurological syndromes (PNS) are a unique subset of paraneoplastic syndromes. Caused by cross-reactive antibodies called onconeural antibodies, these are antibodies produced by the immune system in response to malignant tumors. These onconeural antibodies can attack different parts of the nervous system resulting in various neurological manifestations. Paraneoplastic cerebellar degeneration (PCD) is one of the more commonly seen paraneoplastic neurological syndromes. It is caused by immune-mediated injury to cerebellar Purkinje cells. It is associated with multiple malignancies but, most commonly, breast and pelvic malignancies. PCD has also been reported in patients with Hodgkin lymphoma, gastric cancer, prostate cancer, and small cell lung cancer. PCD can progress rapidly over a few weeks and can result in severe disability.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s10">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s11">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s12">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s13">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s14">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26629" sec="article-26629.s15">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>8</Day></ContributionDate><ReferenceList><Reference><Citation>Zekeridou A, Majed M, Heliopoulos I, Lennon VA. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. Thorac Cancer. 2019 Apr;10(4):1001-1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449272</ArticleId><ArticleId IdType="pubmed">30810271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85(9):838-54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931619</ArticleId><ArticleId IdType="pubmed">20810794</ArticleId></ArticleIdList></Reference><Reference><Citation>Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ, European Federation of Neurological Societies  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011 Jan;18(1):19-e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086523</ArticleId><ArticleId IdType="pubmed">20880069</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012 Dec;25(6):795-801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705179</ArticleId><ArticleId IdType="pubmed">23041955</ArticleId></ArticleIdList></Reference><Reference><Citation>Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, PNS Euronetwork  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010 Mar;67(3):330-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanous I, Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2015;5:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078897</ArticleId><ArticleId IdType="pubmed">27800287</ArticleId></ArticleIdList></Reference><Reference><Citation>Arratibel N, Sobejano E, Moran JC, Diaz LG, Blázquez A, Baile M, Veiga Á, Caballero MD, García-Sanz R. A Case of Paraneoplastic Cerebellar Degeneration that Preceded the Diagnosis of Classical Hodgkin's Lymphoma by 16 Months. Am J Case Rep. 2020 Jun 23;21:e922342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328688</ArticleId><ArticleId IdType="pubmed">32574156</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak M, Kowar M, Sippel C, Wilhelm K, Ko YD, Jacobs AH. [Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies]. Nervenarzt. 2020 Feb;91(2):156-160.</Citation><ArticleIdList><ArticleId IdType="pubmed">31900515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol. 2012 Jan;15(1):6-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299076</ArticleId><ArticleId IdType="pubmed">22412264</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct;42(10):1931-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407575</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol. 2016 Aug;3(8):655-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999597</ArticleId><ArticleId IdType="pubmed">27606347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015 Sep 17;12:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573944</ArticleId><ArticleId IdType="pubmed">26377319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology. 1988 Sep;38(9):1380-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3045692</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal S, Recio M, Shamim S. Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. Proc (Bayl Univ Med Cent) 2015 Apr;28(2):217-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365125</ArticleId><ArticleId IdType="pubmed">25829659</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien TJ, Pasaliaris B, D'Apice A, Byrne E. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J Clin Neurosci. 1995 Oct;2(4):316-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18638835</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91(5):519-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med. 2007 Feb 08;356(6):612-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287482</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulaziz ATA, Yu XQ, Zhang L, Jiang XY, Zhou D, Li JM. Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: Case report. Medicine (Baltimore) 2018 Jun;97(24):e10717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024112</ArticleId><ArticleId IdType="pubmed">29901574</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):525-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077501</ArticleId><ArticleId IdType="pubmed">16543536</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739186</ArticleId><ArticleId IdType="pubmed">15258215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409-18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764061</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003 Jun;63(2):187-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825823</ArticleId></ArticleIdList></Reference><Reference><Citation>Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, Delattre JY. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):479-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736897</ArticleId><ArticleId IdType="pubmed">10727484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato N, Hashida G, Konaka K. Rehabilitation for a patient with anti-Yo antibody-positive paraneoplastic cerebellar degeneration caused by breast cancer: A case report and literature review. Medicine (Baltimore) 2017 Nov;96(44):e8468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682818</ArticleId><ArticleId IdType="pubmed">29095299</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32809473</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
